Form 4: Immunome Director Jean Jacques Bienaime Acquires 7,000 Shares

Director Jean Jacques Bienaime of Immunome Inc. reports the acquisition of 7,000 shares of common stock at an average price of $8.21.

Summary

• On March 24, 2025, Jean Jacques Bienaime, a director of Immunome Inc. (IMNM), acquired 7,000 shares of common stock.
• The shares were purchased at a weighted average price of $8.21, with individual prices ranging from $8.16 to $8.42.
• Following the transaction, Bienaime directly owns 23,615 shares of Immunome Inc.
• The transaction was reported on March 25, 2025.

Sentiment

Score: 6

Explanation: Insider buying is generally a positive sign, suggesting confidence in the company's prospects, but the impact is moderate given the size of the transaction.

Positives

• The director's purchase could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors as they can provide insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Insider buying is generally viewed positively, but its impact varies depending on the size of the purchase relative to the insider's existing holdings and the overall trading volume of the stock.
• Compared to other similar transactions, a purchase of 7,000 shares by a director is a moderate-sized transaction.
• The significance of this purchase would be assessed in the context of Immunome's overall performance and news flow.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The purchase could potentially increase investor confidence in the company.

Key Dates

Keywords

Immunome, Director, Share Acquisition, IMNM, Bienaime, Insider Trading, Form 4